Dalvi Pranjali N, Gupta Vijayalaxmi G, Griffin Brooke R, O'Brien-Ladner Amy, Dhillon Navneet K
Departments of 1 Internal Medicine and.
2 Molecular and Integrative Physiology, University of Kansas Medical Center, Kansas City, Kansas.
Am J Respir Cell Mol Biol. 2015 Sep;53(3):336-45. doi: 10.1165/rcmb.2014-0369OC.
Our previous study supports an additive effect of cocaine to human immunodeficiency virus infection in the development of pulmonary arteriopathy through enhancement of proliferation of pulmonary smooth muscle cells (SMCs), while also suggesting involvement of platelet-derived growth factor receptor (PDGFR) activation in the absence of further increase in PDGF-BB ligand. Redox-related signaling pathways have been shown to regulate tyrosine kinase receptors independent of ligand binding, so we hypothesized that simultaneous treatment of SMCs with transactivator of transcription (Tat) and cocaine may be able to indirectly activate PDGFR through modulation of reactive oxygen species (ROS) without the need for PDGF binding. We found that blocking the binding of ligand using suramin or monoclonal IMC-3G3 antibody significantly reduced ligand-induced autophosphorylation of Y1009 without affecting ligand-independent transphosphorylation of Y934 residue on PDGFRβ in human pulmonary arterial SMCs treated with both cocaine and Tat. Combined treatment of human pulmonary arterial SMCs with cocaine and Tat resulted in augmented production of superoxide radicals and hydrogen peroxide when compared with either treatment alone. Inhibition of this ROS generation prevented cocaine- and Tat-mediated Src activation and transphosphorylation of PDGFRβ at Y934 without any changes in phosphorylation of Y1009, in addition to attenuation of smooth muscle hyperplasia. Furthermore, pretreatment with an Src inhibitor, PP2, also suppressed cocaine- and Tat-mediated enhanced Y934 phosphorylation and smooth muscle proliferation. Finally, we report total abrogation of cocaine- and Tat-mediated synergistic increase in cell proliferation on inhibition of both ligand-dependent and ROS/Src-mediated ligand-independent phosphorylation of PDGFRβ.
我们之前的研究支持可卡因在人类免疫缺陷病毒感染导致肺动脉病发展过程中具有累加效应,其作用机制是通过增强肺平滑肌细胞(SMC)的增殖,同时也表明在血小板衍生生长因子-BB(PDGF-BB)配体未进一步增加的情况下,血小板衍生生长因子受体(PDGFR)的激活也参与其中。氧化还原相关信号通路已被证明可独立于配体结合来调节酪氨酸激酶受体,因此我们推测,同时用转录激活因子(Tat)和可卡因处理SMC,可能能够通过调节活性氧(ROS)间接激活PDGFR,而无需PDGF结合。我们发现,在用可卡因和Tat处理的人肺动脉SMC中,使用苏拉明或单克隆IMC-3G3抗体阻断配体结合可显著降低配体诱导的Y1009自磷酸化,而不影响PDGFRβ上Y934残基的非配体依赖性转磷酸化。与单独使用任何一种处理相比,可卡因和Tat联合处理人肺动脉SMC会导致超氧阴离子自由基和过氧化氢的生成增加。抑制这种ROS生成可防止可卡因和Tat介导的Src激活以及PDGFRβ在Y934处的转磷酸化,同时Y1009的磷酸化没有任何变化,此外还可减轻平滑肌增生。此外,用Src抑制剂PP2预处理也可抑制可卡因和Tat介导的Y934磷酸化增强和平滑肌增殖。最后,我们报告,在抑制PDGFRβ的配体依赖性和ROS/Src介导的非配体依赖性磷酸化后,可卡因和Tat介导的细胞增殖协同增加被完全消除。